drugset
drugset / Trial / NCT03848416

A Study of Ixekizumab in Healthy Participants

NCT03848416 ↗

Phase 1 Completed 99 enrolled Eli Lilly and Company
RandomizedParallel-groupSingle-blindBasic science

Summary

The purpose of this study is to compare three different formulations of ixekizumab. One formulation (Reference) has been approved by the Food and Drug Administration (FDA) and two formulations (Test 1 and Test 2) have not been approved. This study will compare how much of each of the three formulations get into the blood stream. Information about any side effects that may occur will also be collected.

Timeline

Start
2019-01-29
Primary completion
2019-06-07
Completion
2019-06-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixekizumab Monoclonal antibody 80 mg Subcutaneous

Indications

No indication recorded.